Clinical trials: Solid Tumor, completed
Neoplasms, Cancer
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
- Conditions
- Neoplasms, Cancer, Tumors
- Trial name
- NCT01030055
- Testing
- TKI258 (dovitinib)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, NSCLC
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
This is a phase Ib single arm, open-label, multiple dose, dose escalating, safety, pharmacokinetic and pharmacodynamic study of the combination of PF-05212384 with paclitaxel and carboplatin.
- Conditions
- Breast Cancer, NSCLC, Ovary Cancer, Endometrial Cancer
- Trial name
- IOSI-NDU-001 (NCT02069158)
- Testing
- PF-05212384, Paclitaxel, Carboplatin
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Cristiana Sessa
Advanced Solid Tumors, Triple Negative Breast Cancer
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
This is a first-in-human, phase I clinical research study with TT-00420, an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple…
- Trial name
- NCT03654547
- Testing
- TT-00420
- Where
- 2 sites in United States, China
- Volunteers
- 48 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Solid Tumor
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator, but will not be recruiting locally.
- Trial name
- NCT01683149
- Testing
- Topotecan, Sorafenib
- Where
- 9 sites in United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasms
First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory…
- Trial name
- NCT01881217
- Testing
- BAY1179470
- Where
- 8 sites in Japan, Singapore and 1 more
- Volunteers
- 35 people
- Sponsor
- Bayer
Cancer, Advanced Solid Malignancies
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies.
- Trial name
- NCT01813474
- Testing
- olaparib
- Where
- 3 sites in Japan
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Cutaneous Melanoma, Non-small Cell Lung Cancer
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma
- Trial name
- NCT03633110
- Testing
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genocea Biosciences, Inc.
Solid Tumors
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
This study will be conducted in 5 parts (Parts A, B, C, D and E). Monotherapy Treatment: Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A.
- Trial name
- NCT02628574
- Testing
- TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Leap Therapeutics, Inc.
Solid Tumors
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
The purpose of this study is to determine the safety and maximal tolerated dose of NKP-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors.
- Trial name
- NCT01415297
- Testing
- NKP-1339
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Niiki Pharma Inc.
Lung Cancer
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
1. Primary Objective: The primary endpoint to this study will be to document the toxicities, and reversibility of toxicities, of this regimen of hydralazine and valproic acid in patients with advanced, unresectable, previously…
- Trial name
- NCT00996060
- Testing
- Hydralazine and Valproic Acid: Cohort -1, Hydralazine and Valproic Acid: Cohort 0, Hydralazine and Valproic Acid: Cohort 1
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New Mexico Cancer Research Alliance
Unspecified Adult Solid Tumor, Protocol Specific
SJG-136 in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as SJG-136, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00103220
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00884676
- Testing
- Ixabepilone, Sunitinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jaime Merchan
Leukemia, Neoplasms
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
The present trial will be performed according to an open design to determine the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group…
- Trial name
- NCT01971476
- Testing
- volasertib
- Where
- 5 sites in Belgium, Czechia and 3 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Solid Carcinoma, 5-Fluorouracil Toxicity
Prevention of Chest Pain in Chemo-treated Cancer Patients
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment…
- Conditions
- Solid Carcinoma, 5-Fluorouracil Toxicity, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- CATCH (NCT03486340)
- Testing
- Cardiologic assessment
- Where
- Denmark
- Volunteers
- 218 people
- Sponsor
- Vejle Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005791
- Testing
- cisplatin, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer Cachexia
Exploratory Trial of SAT-003 in Cancer Cachexia Patients With Discontinued Chemotherapy
This clinical trial aims to evaluate the feasibility of 'SAT-003' as well as its exploratory safety and efficacy in patients with cancer cachexia who have been diagnosed with solid tumors and have discontinued anticancer…
- Trial name
- NCT06476197
- Testing
- SAT-003
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- S-Alpha Therapeutics, Inc.
Solid Tumor
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to evaluate the safety, tolerability, and PK of IGM-7354 in participants with relapsed and/or refractory tumors.
- Trial name
- NCT05702424
- Testing
- IGM-7354
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- IGM Biosciences, Inc.
Solid Tumor, Lymphoma
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with metastatic or locally advanced solid tumors…
- Trial name
- NCT04306224
- Testing
- IMC-002
- Where
- 4 sites in United States, South Korea
- Volunteers
- 12 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Metastatic Solid Tumors
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options.
- Trial name
- NCT00878423
- Testing
- AT13387
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Locally Advanced and Metastatic Solid Tumors
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217…
- Trial name
- NCT04047862
- Testing
- Ociperlimab, Tislelizumab, Pemetrexed
- Where
- 65 sites in United States, Australia and 4 more
- Volunteers
- 446 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.